PER-017-07已完成未知
A Randomized, Double-blind, Parallel Group Study Evaluating the Safety of Fluticasone Propionate/Salmeterol 100/50 mcg HFA (2 Inhalations of 50/25 mcg) Twice Daily Compared With Fluticasone Propionate 100 mcg HFA (2 Inhalations of 50 mcg) Twice Daily in Subjects 4-11 Years of Age With Persistent Asthma
GLAXOSMITHKLINE PERU S.A.,0 个研究点目标入组 0 人开始时间: 2007年7月4日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Type of Subject: The subject must be treatable on an outpatient basis.
- •2. Age: The subject must be 4-11 years of age in Visit 1.
- •3. Sex: Male or female pre-menarche.
- •4. Illness: All subjects must have a diagnosis of asthma that required pharmacotherapy prescribed by the doctor for at least two months before Visit 1.
- •5. Severity of Disease: At Visit 1, subjects 6-11 years of age should demonstrate a baseline morning clinical FEV1 pre-albuterol> 60% of the predicted Polgar value and subjects of 4 and 5 years of age should demonstrate a pre-albuterol basal AMF morning mat> 60% of the value Predicted Polgar.
- •6. Reversibility Component: A subject must have historical documentation of an increase in FEV1 or FEM of> 12% within 30 minutes after the administration of albuterol or levalbuterol within 24 months before Visit 1.
- •7. Concurrent anti-asthma therapy: Subjects are eligible to participate in the trial if they have been using an inhaled corticosteroid at a consistent dose for at least one month prior to Visit 1.
- •8. All subjects should be able to replace their short-acting B2-agonist with the aerosolized albuterol.
- •9. Maximum Flow Meter / Journal Book: The subject should be able to use the maximum flow meter supplied in the study and the subject / caregiver should be able to keep the record in the journal book.
- •10. Subjects (6-11 years of age) should be able to adequately perform the spirometry maneuver and maintain effort for at least 3 seconds.
排除标准
- •1. Life-threatening asthma: The subject should not have potentially fatal asthma.
- •2. Medications for asthma: Medications prohibited for asthma listed should not have been used before Visit 1 during the required interval and should not be taken during the study.
- •3. Corticosteroid therapy: The use of any medication with corticosteroids that is not the study medication is prohibited.
- •4. Excluded medications: Except where otherwise indicated, concurrent use of any prescription medication with or without a prescription that may affect the course of asthma, or that interacts with other medications required by this protocol, will not be permitted during the study. .
- •5. Immunosuppressive Drugs: The use of immunosuppressive drugs will not be allowed.
- •6. Concurrent diseases / abnormalities: Historical or current evidence of clinically significant, uncontrolled disease.
- •7. Varicella: A subject will not be eligible if they have chickenpox, or have been exposed in the last three weeks and are not immune.
- •8. Pharmacological Allergy: Any immediate or delayed hypersensitivity to a B2-agonist, sympathomimetic or intranasal, inhaled, or systemic corticosteroid therapy.
- •9. Infections: Sinus, middle ear, oropharynx, upper or lower respiratory tract infections within two weeks prior to Visit 1 that required the use of antibiotics or that were accompanied by symptoms of worsening asthma.
- •10. Use of tobacco.
- •11. Clinical laboratory abnormalities: Clinically significant abnormal laboratory tests during Visit 1.
- •12. ECG: The subject is not eligible if they have an abnormal, clinically significant ECG or a QTc interval> 449 msec.
- •13. Ophthalmological: History or presence of glaucoma and / or posterior subcapsular cataracts.
- •14. Research Drugs: Any investigational drug used for any indication is prohibited within 30 days prior to Visit 1.
- •15. Attendance: A subject will not be eligible if he / she or his parents or legal guardians have any illness, disability, or geographic location that could impede compliance with any aspect of the study protocol or scheduled visits to the study center.
- •16. Informed Consent: A subject will not be eligible if he / she or his parents or legal representatives have a history of psychiatric illness, intellectual disability, low motivation, substance abuse, or other conditions that limit the validity of informed consent to participate in This studio.
- •17. Affiliation with the investigator´s center: A subject will not be eligible for this study if he / she is an immediate member of the family of the participating researcher, sub-investigator, study coordinator, or employee of the participating investigator.
研究者
相似试验
已完成
不适用
A clinical trial of a functional food product in Regulating Blood Glucose in Type 2 Diabetic patientsCTRI/2018/02/012081ITC Life Sciences and Technology Center ITC Ltd450
进行中（未招募）
不适用
A Randomized, Double-blind, Parallel-group Study to Investigate the Efficacy, Safety and Tolerability of Cariprazine in Patients with Predominant Negative Symptoms of SchizophreniaPatients with Predominant Negative Symptoms of SchizophreniaMedDRA version: 16.0Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2012-005485-36-ESGedeon Richter Plc420
进行中（未招募）
不适用
A Randomized, Double-blind, Parallel-group Study to Investigate the Efficacy, Safety and Tolerability of Cariprazine in Patients with Predominant Negative Symptoms of SchizophreniaEUCTR2012-005485-36-BGGedeon Richter Plc420
进行中（未招募）
不适用
A Randomized, Double-blind, Parallel-group Study to Investigate the Efficacy, Safety and Tolerability of Cariprazine in Patients with Predominant Negative Symptoms of SchizophreniaEUCTR2012-005485-36-PLGedeon Richter Plc420
进行中（未招募）
1 期
A Randomized, Double-blind, Parallel-group Study to Assess the Safety and Efficacy ofAsacol® (1.2 to 4.8 g/day) Administered as 400 mg Delayed-release Tablets Given Every 12 Hours for 6 Weeks to Children and Adolescents with Mildly-to-Moderately Active Ulcerative Colitis. - CAMP IIMildly-to-Moderately Active Ulcerative Colitis in Children and AdolescentsMedDRA version: 11.0Level: LLTClassification code 10045365Term: <Manually entered code. Term in E.1.1>EUCTR2007-005702-49-PLProcter & Gamble Pharmaceuticals100